US OptionsDetailed Quotes

FOLD240719C8000

Watchlist

1.55
0.000.00%

15min DelayClose Jul 8 16:00 ET

0.00High0.00Low

Amicus Therapeutics Stock Discussion

Meltyy

May 16 01:29

🔔 Perceptive Advisors Q1 ‘24* Holdings Released... 🐳

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US)$
$Amicus Therapeutics(FOLD.US)$
$Iovance Biotherapeutics(IOVA.US)$
$Arcellx(ACLX.US)$
$Nuvalent(NUVL.US)$
$Apogee Therapeutics(APGE.US)$
$Inhibrx(INBX.US)$
$Fusion Pharmaceuticals(FUSN.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Vaxcyte(PCVX.US)$
$Soleno Therapeutics(SLNO.US)$
$Medtronic(MDT.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
...

Moomoo AI

Feb 7 06:42

Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.

Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

Jan 3 05:28

Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Shares Climb 28% But Its Business Is Yet to Catch Up

Mini0n

Sep 28, 2023 11:13

$Amicus Therapeutics(FOLD.US)$ Good thing this didn't have any bad news, jesus

73015995

Sep 28, 2023 10:06

$Amicus Therapeutics(FOLD.US)$ FDA approval 🚀🙏🏻

Mini0n

Sep 28, 2023 07:50

$Amicus Therapeutics(FOLD.US)$ News halt...... watching

Mantou

Aug 15, 2023 22:56

Amicus announces U.K. approval and launch of Pompe disease therapy

$Amicus Therapeutics(FOLD.US)$

Alvinnnnnnngenius

Aug 15, 2023 06:37

$Amicus Therapeutics(FOLD.US)$ Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis.
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.

WallStreetYoda

Oct 13, 2022 14:09

$Amicus Therapeutics(FOLD.US)$ Following the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at approximately $7,261,677.54. he just needed the money for somthing if it was bad news we dont know yet then he would have sold way more

Mcsnacks H Tupack

Sep 29, 2021 06:45

$Editas Medicine(EDIT.US)$ to release phase 1/2 study results.
$Amicus Therapeutics(FOLD.US)$ applies for FDA approval and Is merging a new company.

No comment yet